🔴 Chimeric Therapeutics is trading 5.26% down today after CHM-2101 Phase 1 dosing ceased

Chimeric Therapeutics is trading 5.26% down now at A$0.02 after resuming trading following the August 19 disclosure that enrolment and dosing in the CHM-2101 Phase 1 trial had ceased.

• The decision followed dose-limiting toxicity in a second patient at Dose Level 3.
• The company is shifting focus toward an in vivo CDH17 therapy and plans approximately A$4 million in annual cost reductions.
• The August 20 decline appears to continue the sharp post-announcement selloff rather than reflect a new catalyst.